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ABSTRACT 
People in every country became exposed to COVID-19 pandemic and cannot able to find a right solution and strategies to overcome from it. 
Pharmacy is the most important, dynamic and versatile health care profession in the world, whereas its scope and importance are always being 
emerging at any situation. Pharmacy professionals (PPs) working proactively for the public even in this pandemic situation. Since dependency is 
high, the responsibility and preference also high for PPs especially in this pandemic situation. Current status in pharmacy education and emerging 
future challenges of PPs in all aspects, particularly in this pandemic situation were addressed based on observational studies among various pharma 
industries and published news of Pharmacy Council of India (PCI). While in the development phase it has crossed many barriers, not only in the 
economic level, but also involves regulations, duration, process controls, legal hurdles and situational defects. The purpose of this review discusses 
the evolution and updates in pharmacy, education, pharmacy practice, regulations, and types of challenges along with recommendations for PPs in 
India in light of the COVID-19 pandemic.  
This review was carried out to summarize knowledge about the updates and challenges in pharmacy professions in all aspects. Sources were 
retrieved from relevant guidelines and published articles in Google scholar, Pubmed and Science direct of articles up to June 2020. The keywords 
used for gathering information were listed below. 
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INTRODUCTION 
People in every country became exposed to COVID-19 pandemic and 
not able to find a right solution and strategies to overcome from it. 
Pharmacy is the most important, dynamic and versatile health care 
profession in the world, whereas its scope and importance are always 
being emerging at any situation [1]. Pharmacy professionals (PPs) 
working proactively for the public even in this pandemic situation. 
Since dependency is high, the responsibility and preference also high 
for PPs especially in this pandemic situation. The pharmacy zone is an 
adaptable, developing and progressively different one, which has a 
huge number of chances for work and administration aspects [2]. PPs 
are human service experts whose proficient obligations incorporate to 
protect the individuals by dispensing medicines with prescriptions [3]. 
It represents the third biggest medicinal services with active gathering 
in the world and in India there are more than 1,000,000 (1 Million) 
enrolled PPs working in different positions contributing to the 
wellness of the country. Pharmacy is being a significant profession, 
since the Indian government passed the Pharmacy Act 1948 to control 
the pharmacy stores by following instructions to control the 
manufacturing, distribution and marketing [4]. Health care in the 
genuine sense called as pharmacy practice which incorporates; 
clinical, community and hospital pharmacy. PPs shape an imperative 
connection between doctors, nurses and the patients in the social 
community group with an ultimate focus on patient welfare and safety 
[5]. Pharmacists cannot be only the distributors, but also they need to 
offer some contributions to the society, including administrations such 
has patient counselling, guiding and arrangement of medication data 
to human services, suppliers as well as patients [6]. The pharma 
industry performed well after the amendment of new monetary 
changes in India in the mid-1990s till the early 2000s, for example, 
before the product patent was introduced in India [7]. In educational 
aspects level of student’s outcome in pharmacy also have been 
increased from the year of 2012 to 2020 and still expected to rise due 
to its scope. Many of the pharmacy graduates showing potential 
interest in the research side for drug innovation and development [8]. 
It has been viewed that pharmacy as a significant job in improving 
social insurance as they work day and night to keep up a chain of 
elegant integrity on pharmaceuticals especially during a COVID-19 
pandemic. PPs has many roles and responsibilities right from the 
perspective of regulatory authorities in performing implementation of 
updated guidelines based on the situation defects [9]. 
Pharmacy practice  
It includes implementation, evaluation and interpretation of 
pharmacy orders and prescription dispensing. Pharmacists are 
responsible for providing patient counselling, provisions for acts 
and social services required to promote pharmaceutical care in all 
areas of patient health as a primary care [10]. They are also 
responsible for the segregation, labelling of drugs and medical 
devices, by ensuring safety on proper storage of drugs and devices 
along with maintenance of proper records [11].  
According to Supreme Court judgment of 5th
• Pharmacy Act is a pre-constitutional act 
March 2020 
• There cannot be two regulators 
• AICTE act is a general act 
• Pharmacy act is a special act 
• Pharmacy act is a complete code with pharmacy experts 
• Pharmacy Council of India (PCI) alone shall prescribe 
qualification for pharmacist 
• PCI alone shall prescribe norms for pharmacy institutions 
• Approval and intake in institutes be decided by PCI alone 
• Pharmacy act can regulate not only pharmacy education, but 
profession also [12] 
Pharmacy professions in India 
• Pharma industry 
• Community pharmacy 
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• Pharmaco-vigilance 
• Pharmacy education 
• Pharma regulatory practice 
First pharmaceutical company in India 
Bengal chemical and pharmaceuticals Ltd., was set up as an initiative 
by the individual, started a laboratory in 1892 by the ‘Father of 
Indian chemistry’ Acharya Prafulla Chandra Ray and regarded the 
country’s first pharma company. Bengal chemicals and 
pharmaceuticals Ltd. has reached profits for a year 2016-17 for the 
first time after more than six decades [13]. 
Drug regulation  
India has the world's toughest legislation and laws for manufacture, 
distribution and sale of medicines. The law enforcement’s ability 
does not translate by strong legislation alone; it also involves strict 
regulations and accepting effective challenges. There should be one 
drug inspector for every 50 manufacturing units and one per 200 
distribution retailers, according to the regulation set out by the 
Mashelkar committee [14, 15]. In most of the state’s 30-50% of the 
posts remain vacant and the number of posts that exists also is 
highly inadequate for expanding the pharmacy sector. As per the 
Mashelkar committee report, 1 drug inspector for 200 retailers was 
taken into consideration and among the data of All India 
Organization of Chemists and Druggists (AIOCD), around 8.5 lakh 
pharmacies is to be taken cognizance, so more than 4250 drug 
inspectors needed to manage the retail pharmacy segment [16].  
Division of responsibilities between CDSCO and SDRA 
Pre-manufacturing 
Central Drugs Standard Control Organization (CDSCO) regulates pre-
manufacturing with the help of expert committees. Their key role in 
dealing with the two major criteria is:  
• Clinical trials (Clinical trial registry, Good Clinical Practices 
(GCP), inspections, ethics committee and serious adverse events) 
• New drug approvals (import and marketing license) [17]. 
Manufacturing 
State Drug Regulatory Authority (SDRA) is responsible for 
regulating the manufacture of drug products in the states, whereas 
CDSCO is responsible for union territories. CDSCO and SDRAs also 
conduct joint inspections in certain cases [18]. The following terms 
are necessary for the manufacturing of drug products.  
• License (generic and marketing license) 
• Inspection of Good Manufacturing Practices (GMP) 
• Drug testing and prosecution for non-compliance[19] 
Distribution and sale 
SDRA’s are responsible for regulating the distribution and sale of 
drug products in the states, while CDSCO is responsible for union 
territories. The following terms are necessary for the distribution 
and sale of drug products. 
• License (sale and distribution practices) 
• Inspection of Good Distribution Practices (GDP) 
• Drug testing and prosecution for non-compliance[20] 
Current status  
The current status in pharmacy education, authority functions and 
future challenges of PPs in all aspects, particularly in this COVID-19 
pandemic were addressed. While in the development phase, it has to 
cross many barriers, not only in the economic level but also involves 
regulations, duration, process controls, legal hurdles and situational 
defects [21]. The educational updates were presented in table 1. 
 
Table 1: Statistics of pharmacy education program in India 
Pharmacy program Number of institutions Annual intake 
D Pharm 3022 180,770 
B Pharm 1961 125,524 
Pharm D 267 8010 
M Pharm 792 24,465 
Ph. D. in Pharmacy 31 1240 
  
COVID-19 and the impact 
The impact of the SARS-CoV2 outbreak, COVID-19 has exposed the 
dependence of the Indian pharma sector on china for its Active 
Pharmaceutical Ingredient API obtainment, since India as well as 
other countries had decided to stop business contract with china. 
Gracefully, chain circulation and exportation limitations from India 
came out because of manpower deficiencies in china's 
manufacturing plants [22]. This was brought by the isolated 
arrangements adjusted and embraced by various common 
governments in china in response to the infection. Supplies were 
additionally affected by the interruption of coordination, 
transportation frameworks, confining access and exchange of items 
to and from ports [23]. More over the customers who are coming for 
pharmacy stores may be positive for COVID-19 but remain as 
asymptomatic, so this will impact the pharmacist to get spread, 
whereas in hospital pharmacy if this same incident happens, then 
there is an easy chance of getting more spread among the patients 
who came to hospital since they may be weaker in health and being 
low immune [24, 25]. 
Indian government strategies for API stimulation-atmanirbar 
bharat 
The government has announced about promotion of common 
infrastructure facilities in three ‘Bulk Drug Parks’ (BDP) with the 
financial investment of INR 3,000 crore in the next five years. The 
government will provide grant-in-aid scheme to the states with a 
maximum limit of INR 1,000 crore per BDP, which having general 
facilities such as solvent recovery plant, distillation plant, common 
effluent treatment plant, power and steam units [26]. It will create a 
Production Linked Incentive (PLI) scheme for promotion of 
domestic manufacturing of critical Key Starting Materials (KSM), 
intermediates of drug and Active Pharmaceutical Ingredients (APIs) 
in the country with the financial implications of INR 6,940 crore for 
the next eight years [27]. 
 
 
Fig. 1: Incentive details of the proposed scheme [29] 
 
Initiative by the government 
PLI Scheme is open for four months from June 2, 2020 will allow 
investors to propose the establishment of Greenfield facilities for any 
of the 53 key drug intermediates and bulk drugs that are hardly 
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manufactured in India today [28]. The list includes key ingredients 
that go into the manufacturing of commonly prescribed medicines like 
paracetamol, aspirin, metformin, atorvastatin, etc. The total proposed 
incentive package contains Rs. 13,760 crore, that is segregated for bulk 
drugs and medical devices were classified below in fig. 1. 
Challenges associated with PPs  
COVID-19 challenges 
• Millions affected globally 
• No cure insight 
• Digital (online) education 
• Test for Indian strategy and approach 
• Expectations in Indian pharmaceutical sector in the global visibility  
• Challenges in opportunities 
Regulatory challenges 
This segment suffers from the problem of information asymmetry 
across the different layers of regulatory and enforcement mechanisms. 
There is a large variance in the quality of drug regulation across states 
in the country, since each state having their own regulations [30]. Drug 
inspectors of India who are the key players in drug regulations should 
be made highly qualified and be well paid to bring about the dignity 
associated with the huge responsibility. There is a budget constraint 
with the department for implementation of advanced methods of 
monitoring the regulations [31]. 
Pharma industry-future challenges 
There is a huge expectation, price pressure and carefulness in 
monitoring of vaccine development, especially (Covaxin) for treatment 
of COVID-19, which is still under the Phase I and II clinical trial in India. 
There may be a chance of unsatisfactory results occur in Phase III trial, 
whereas many countries faced the issue on Phase III trial, which 
resulted failure in vaccine development and outcome [32]. Nowadays 
there are emerging challenges in the management of process controls 
during a formulation of pharmaceuticals is the formation of impurities, 
which are in the form of genotoxic and carcinogenic that are highly 
toxic and harmful for the patients who were taking medication for the 
management of diabetes, gastric ulcer and psychosis [33]. There is also 
a compensation challenge for the loss of Fixed Dose Combination 
(FDC) drugs in India, since many of the drugs around 344 under this 
category were banned and withdrawn due to they are therapeutically 
irrational and produced toxicity to the patients for treatment of 
chronic diseases like tuberculosis and HIV. So there are still 
expectations of producing FDCs, into the market for patient 
beneficence with assurance in the safety and efficacy [34]. The quality 
of research, drug discovery and development is suboptimal if the 
money investment is not strengthened.  
Digital education 
Holon IQ global education intelligence, a provider estimates that the 
present education sector size of $6 trillion will reach $10 trillion by 
2030. Only 3% of the global education spends is digital platform and 
by 2025 the digital spend will be $325 billion, which is less than 5% 
of the global education spend [35, 36]. The present challenges faced 
by the government are the seamless delivery of education in the 
post-covidian direction of digital education, but this will be a far 
cure for the education disorders in the country [37]. The UGC is in 
the process of developing a game-changing policy where the 
universities that have a high ‘NAAC’ score among the top 100 NIRF 
rankings will be permitted to offer online programs. This will be a 
game-changer as the jurisdiction of education will become global 
and only those universities which are equipped will survive [38]. 
Recommendations 
Based on the unique situation faced by the every country due to 
COVID-19, the recommendations were executed below for the PPs:  
• The pharma industry needs to get out of the COVID-19 based 
mindset and start focusing on the needs of the country and 
strategies to work despite the policy and regulatory challenges. 
• Adequate funding should be given by the government to the 
researchers of PPs for the new drug development and for conducting 
clinical trials. 
• The pharma industry should learn to invest in quality manpower 
to get the desired outcomes and shift the focus from the product to 
the patient [39]. 
• Interpretation of state and central guidelines to protect the 
public health and disease control management. 
• Strengthening the regulations on health care management and 
professionals to follow strict rules based on the states. 
• There should not be a significant dependency for API 
procurement from china, instead of that, steps to be taken for API 
supply from own country itself. 
• Enabling workflow modifications in principles while handling 
emergency situations 
• To create awareness and educational training programs to 
safeguard physical and mental health among each individual during 
this pandemic situation.  
• The pharmacognosy and phytopharmacy department should 
focus on herbal and ayurvedic formulation development to fight 
against COVID-19 as naturopathy based treatment.  
• The positive, believable and evidence based advertisements to 
be done by the PPs regarding the traditional method of AYUSH 
based medications to fight against COVID-19. 
• The public should consume “Kapasura kudineer” that is readily 
available in retail pharmacy especially in south India that contains 
many combinations of herbs that can combat corona virus and other 
microorganisms, this have shown positive results, since many 
people got benefited and relieved from COVID-19 in asymptomatic 
reported positive cases.  
• Steps to be taken for e-learning/webinar programs to get more 
updates from the WHO and health advisory committee for the 
pharmaceutical development and public health protection. 
• Utilization of PPs as second line healers or physicians to 
diagnose the patient’s illness in case of emergency [40]. 
• Enabling e-prescriptions and home delivery of medicines to the 
self-isolated individuals during COVID-19 outbreak and older 
persons by ensuring precautionary measures and safety. 
• Advocacy with policy makers and stakeholders needs to be 
strengthened to get the right regulatory environment that can 
stimulate growth of the pharmaceutical industry. 
CONCLUSION 
The Indian pharmaceutical industry has experienced a wide strategy 
changes that is expected to affect the execution of national as well as 
regional level. Although the greater part of the states recovered from 
the serious issues and gave indications of nearly better execution 
from the year 2007 to 2011, but there is still an emerging challenges 
and lack of developments to reach the benchmark when compared 
to other developed countries. From the overall study, key elements 
are money investment, educational trainings, awareness programs 
and recommendations, which is highly required for PPs to expand 
their roles in bringing up navigation for greater development in 
quality of pharmaceuticals to defend any challenges, health issues 
and deadly disease like COVID-19, so ultimately the recognition will 
reach globally for PPs in India. The money investment from the 
government or funding agency should come forward and contribute 
to the researchers in bringing up the development for better quality 
pharmaceuticals to defend any health issues and deadly diseases like 
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